Wells Fargo & Company Bio Line Rx Ltd. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BLRX
# of Institutions
38Shares Held
3.35MCall Options Held
46.5KPut Options Held
6.3K-
Alyeska Investment Group, L.P. Chicago, IL866KShares$190,6280.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$179,4504.05% of portfolio
-
Envestnet Asset Management Inc239KShares$52,6200.0% of portfolio
-
Morgan Stanley New York, NY198KShares$43,4580.0% of portfolio
-
Values First Advisors, Inc.198KShares$43,4530.06% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $13.5M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...